Gore announced the expansion of the GORE TAG Conformable Thoracic Stent Graft with ACTIVE CONTROL System product line, following FDA approval of four new large-diameter tapered designs ― 34x28 mm, 37x31 mm, 40x34 mm and 45x37 mm.
News of the approval comes in conjunction with the first U.S. commercial implant, completed at Keck School of Medicine of USC by Sukgu Han, M.D., M.S., Chief of the Division of Vascular Surgery and Endovascular Therapy at USC.
First approved in 2019, the GORE TAG Conformable Thoracic Stent Graft with ACTIVE CONTROL System is indicated for the endovascular repair of all lesions of the descending thoracic aorta, including aneurysms, transections and Type B Dissections. See full indications for use below.
With its staged delivery system designed for controlled precision, the Gore device is a treatment choice in thoracic aortic disease.
